Dr. Zefei Jiang：Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial

Dr. Zefei Jiang：Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial

2025.02.14
In a significant advancement in cancer research, Dr. Zefei Jiang and his team from The Fifth Medical Center of  Chinese PLA General Hospital published the article "Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial" in Nature Medicine(IF=83) on January 1, 2024. This pivotal study investigates the efficacy and safety of combining toripalimab, an immune checkpoint inhibitor, with nab-paclitaxel in treating metastatic or recurrent triple-negative breast cancer (TNBC). TNBC, marked by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, presents limited treatment options and a poor prognosis. The study addresses the urgent need for more effective therapies for this aggressive breast cancer subtype.
Dr. Yongmei Yin：Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial

Dr. Yongmei Yin：Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial

2025.02.13
In a significant advancement in cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article "Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial" in JAMA Oncology on April, 2024. This pivotal study investigates the efficacy and safety of MW032, a proposed denosumab biosimilar, in treating solid tumor-related bone metastases. Bone metastases, a common and severe complication in cancer patients, lead to skeletal-related events (SREs) that significantly impact morbidity and mortality. The study addresses the urgent need for more effective and accessible treatments for patients suffering from these severe complications.
The 8th Yunling Breast Cancer Summit Forum | Dr. Qianjun Chen: Focusing on Controversies in HER2-Positive Breast Cancer, Multidisciplinary Collaboration Holds Great Promise

The 8th Yunling Breast Cancer Summit Forum | Dr. Qianjun Chen: Focusing on Controversies in HER2-Positive Breast Cancer, Multidisciplinary Collaboration Holds Great Promise

2025.02.13
On July 14, to mark the 40th anniversary of Yunnan Cancer Hospital, the "8th Yunling Breast Cancer Summit Forum," hosted by the Yunnan Anti-Cancer Association and the Chinese Medical Education Association, was held in Kunming. The event gathered cutting-edge advances in breast cancer from domestic and international experts. Dr. Qianjun Chen from Guangdong Provincial Hospital of Traditional Chinese Medicine delivered a keynote report on "Consensus and Controversies in Anti-HER2 Therapy for HER2-Positive Breast Cancer." "Oncology Frontier" interviewed Professor Chen on site to share insights on the consensus and controversies in anti-HER2 therapy for HER2-positive breast cancer, guiding multidisciplinary collaboration to optimize patient management strategies, extend patient survival, and improve quality of life.
Blood Science Update: Gut Microbiota in Benign and Malignant Hematopoiesis

Blood Science Update: Gut Microbiota in Benign and Malignant Hematopoiesis

2025.02.13
This article, published in the esteemed journal Blood Science, highlights the intricate role of gut microbiota in hematopoiesis, encompassing its influence on both benign and malignant conditions. As a peer-reviewed platform at the forefront of clinical and experimental hematology, Blood Science is recognized for its impact on advancing our understanding of molecular biology, physiology, and clinical applications. Authored by Professor Tao Cheng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Med-ical College, Professor Hui Cheng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Med-ical College and Professor Pengxu Qian from the First Affiliated Hospital, Zhejiang University School of Medicine，this work provides crucial insights into the therapeutic implications of gut microbiota for hematological health and disease management.